JPMorgan Chase & Co. reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report published on Sunday, April 30th. The brokerage currently has a GBX 4,500 ($58.09) price objective on the biopharmaceutical company’s stock, up from their previous price objective of GBX 4,200 ($54.21).
AZN has been the topic of a number of other reports. Liberum Capital restated a buy rating and issued a GBX 5,100 ($65.83) price objective on shares of AstraZeneca plc in a research note on Thursday, April 27th. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($77.45) price objective on shares of AstraZeneca plc in a research note on Friday, April 28th. Berenberg Bank dropped their price objective on shares of AstraZeneca plc from GBX 5,500 ($71.00) to GBX 5,450 ($70.35) and set a buy rating on the stock in a research note on Tuesday, February 21st. Deutsche Bank AG restated a buy rating and issued a GBX 5,500 ($71.00) price objective on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Finally, Societe Generale restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Five analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 5,001.80 ($64.56).
Shares of AstraZeneca plc (LON:AZN) traded down 0.41% on Friday, hitting GBX 5119.00. The stock had a trading volume of 2,921,092 shares. The company has a 50-day moving average of GBX 4,801.40 and a 200-day moving average of GBX 4,560.72. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market cap is GBX 64.81 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.